Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting

Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an an...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 2; no. 4; p. e23700
Main Authors Birklé, Stéphane, Desselle, Ariane, Chaumette, Tanguy, Gaugler, Marie-Hélène, Cochonneau, Denis, Fleurence, Julien, Dubois, Nolwenn, Hulin, Philippe, Aubry, Jacques, Paris, François
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.04.2013
Landes Bioscience
Subjects
antiangiogenic therapy
antibody
Author's View
Gb3
glycosphingolipid
Gb3
glycosphingolipid
antiangiogenic therapy
antibody
Online AccessGet full text
ISSN2162-402X
2162-4011
2162-402X
DOI10.4161/onci.23700

Cover

More Information
Summary:Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors equally contributed to the manuscript.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.4161/onci.23700